ASXL1 and myelodysplastic syndrome: The ASXL1 mutation is another epigenetic modifier which is identified in approximately 10–20% of MDS, with frameshift mutations and heterozygous point mutations being identified in about 70% and 30%, respectively, both of which are associated with adverse prognostic outcome and shorter OS [37,88,89].